$407 Million is the total value of Foresite Capital Management V, LLC's 16 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 52.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Pardes Biosciences Inc | $153,886,000 | – | 9,400,515 | +100.0% | 37.81% | – | |
| Somalogic, Inc. | $62,000,000 | -6.1% | 5,326,472 | 0.0% | 15.23% | -25.7% | ||
| New | TheseusPharmaceuticals, Inc. | $40,737,000 | – | 3,212,732 | +100.0% | 10.01% | – | |
| QSI | Quantum-Si Incorporated | $18,432,000 | -5.6% | 2,342,061 | 0.0% | 4.53% | -25.4% | |
| ACRS | Aclaris Therapeutics, Inc. | $18,295,000 | -19.2% | 1,258,243 | 0.0% | 4.50% | -36.1% | |
| CGEM | Sell | Cullinan Oncology, Inc. | $17,637,000 | -71.4% | 1,143,006 | -58.2% | 4.33% | -77.4% |
| Cue Health Inc. | $15,660,000 | +13.5% | 1,167,782 | 0.0% | 3.85% | -10.2% | ||
| KNTE | Kinnate Biopharma Inc. | $15,505,000 | -23.0% | 875,001 | 0.0% | 3.81% | -39.2% | |
| CMPX | New | Compass Therapeutics, Inc. | $13,948,000 | – | 4,400,000 | +100.0% | 3.43% | – |
| Buy | Adagio Therapeutics, Inc. | $12,669,000 | -76.6% | 1,745,060 | +36.3% | 3.11% | -81.5% | |
| ACET | New | Adicet Bio, Inc. | $11,893,000 | – | 680,000 | +100.0% | 2.92% | – |
| HIMS | Buy | Hims & Hers Health, Inc. | $11,180,000 | +40.3% | 1,706,922 | +61.5% | 2.75% | +10.9% |
| GMTX | Gemini Therapeutics, Inc. | $7,086,000 | -28.0% | 2,435,125 | 0.0% | 1.74% | -43.1% | |
| RACB | Research Alliance Corp. II | $4,885,000 | -0.8% | 500,000 | 0.0% | 1.20% | -21.6% | |
| ME | Sell | 23andMe Holding Co. | $2,710,000 | -57.3% | 406,913 | -41.9% | 0.67% | -66.2% |
| PHVS | Sell | Pharvaris N.V. | $491,000 | -92.4% | 34,142 | -90.6% | 0.12% | -94.0% |
| LHDX | Exit | Lucira Health, Inc. | $0 | – | -485,000 | -100.0% | -0.24% | – |
| HLXA | Exit | Helix Acquisition Corp. | $0 | – | -250,000 | -100.0% | -0.77% | – |
| PHICU | Exit | Population Health Investment Co., Inc.unit | $0 | – | -960,000 | -100.0% | -1.74% | – |
| FSII | Exit | FS Development Corp. II | $0 | – | -602,500 | -100.0% | -1.86% | – |
| NRIX | Exit | Nurix Therapeutics, Inc. | $0 | – | -451,522 | -100.0% | -4.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.